IE 11 is not supported. For an optimal experience visit our site on another browser.

China orders halt to gene-editing after scientist's claims

Scientist He Jiankui said this week that he used a gene-editing technology known as CRISPR-Cas9 to alter the embryonic genes of the twin girls born this month.
Image: He Jiankui in 2018
Scientist He Jiankui speaks during an interview in Shenzhen in southern China's Guandong province.Mark Schiefelbein / AP file

SHANGHAI — The Chinese government on Thursday ordered a temporary halt to research activities for people involve in the editing human genes, after a Chinese scientist said he had edited the genes of twin babies.

Scientist He Jiankui said this week that he used a gene-editing technology known as CRISPR-Cas9 to alter the embryonic genes of the twin girls born this month.

He's announcement, which has not been verified, sparked an international outcry about the ethics and safety of such research.

"The nature of this incident is extremely nasty, and relevant bodies have been ordered to temporarily halt the scientific research activities of relevant personnel," the state news agency Xinhua said, citing the health ministry, science and technology ministry and China Association for Science and Technology.

The organizers of a conference where He claimed to have edited the genes also condemned the work on Thursday, calling it "deeply disturbing" and "irresponsible."

"Even if the modifications are verified, the procedure was irresponsible and failed to conform with international norms," the organizing committee of the Second International Summit on Human Genome Editing, being held in Hong Kong this week, said in a statement.

The committee called for an independent assessment of He's claims.

He said gene editing would help protect the girls from infection with HIV, the virus that causes AIDS.

Chinese scientists have also condemned the work and the Southern University of Science and Technology, where He is on leave from his position as an associate professor, has announced an investigation.

The Guangdong province Health Commission said on its website on Wednesday it and Shenzhen city had set up a team to investigate the case.

He's filing to a Chinese clinical trials database indicates that a hospital did an ethical review of the project, but the hospital involved denied that its ethics review committee ever met to discuss the work.

He said after his presentation on Wednesday he was proud of what he had done.

The presidents of the U.S. National Academy of Sciences (NAS) and the U.S. National Academy of Medicine (NAM) also expressed concern about He's work.

"The events in Hong Kong this week clearly demonstrate the need for us to develop more specific standards and principles that can be agreed upon by the international scientific community," NAS president Marcia McNutt and NAM president Victor Dzau said in a statement.